Predicting resistance to dasatinib therapy for patients with Philadelphia-positive leukemia with prior tyrosine kinase inhibitor failure

Leuk Lymphoma. 2015 Jul;56(7):1922-3. doi: 10.3109/10428194.2014.999332. Epub 2015 Jan 21.
No abstract available

Publication types

  • Comment

MeSH terms

  • Dasatinib / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Mutation / genetics*

Substances

  • Fusion Proteins, bcr-abl
  • Dasatinib